Extended release preparation
AssigneesTaisho Pharmaceutical Co., Ltd., Nissan Chemical Industries, Ltd.
InventorsNoriyuki Hirasawa, Nobuyoshi Kamikido, Akihiko Tasaki, Shusei Ito
Life of this patent
Estimating the term…
Loading patent…
AssigneesTaisho Pharmaceutical Co., Ltd., Nissan Chemical Industries, Ltd.
InventorsNoriyuki Hirasawa, Nobuyoshi Kamikido, Akihiko Tasaki, Shusei Ito
Estimating the term…
Disclosed is a sustained release preparation which releases a poorly soluble medicinal agent in a pH-independent manner. Also disclosed is a sustained release preparation which is capable of controlling the Cmax of a medicinal agent to an adequate amount and is thus capable of maintaining the level of the medicinal agent in the blood to a level at which medicinal effects can be expected for a long period of time. Specifically disclosed is a sustained release preparation which is characterized by containing a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone, and hypromellose. An organic acid is blended in the sustained release preparation in an amount of less than 1% by mass.
A sustained release preparation characterized in that the sustained release preparation contains a pharmaceutically acceptable salt of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone and hypromellose, and an organic acid is blended in the sustained release preparation in an amount of 0.5% by mass or less;
Dependencies are inferred from the claim text.